Myeloproliferative Neoplasms - AYAs and Elderly: Two Sides of the Same Coin? A multicenter non-interventional study of East German Hematology and Oncology Study Group (OSHO)

• Conditions: D47.4; D45; D47.3; Osteomyelofibrosis; Polycythaemia vera; Essential (haemorrhagic) thrombocythaemia

• Registration Number: DRKS00023581
• Lead Sponsor: Martin-Luther-Universität Halle-Wittenberg

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2022-02-21
• Study Completion: 2022-07-06
• Results First Posted: 2023-06-01
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 127

Inclusion Criteria

Age = 18 years
- Signed informed consent
- Patients must fulfil WHO diagnostic criteria fpr myelofibrosis (MF), essential thrombocythemia (ET), or polycythemia vera (PV)

Exclusion Criteria

- Limited legal capacity or lack of legal capacity
- Age < 18 years
- BCR-ABL-positive chronic myeloid leukemia (CML)

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Identify the difference in genotypes between adolescents and young adults from 18 and 39 years (AYA) and Elderly cohorts with Myeloproliverative neoplasia (MPN)

Secondary Outcome Measures

Name	Time	Method
- Difference in gene expression profiles between AYA and Elderly patients<br>- Delineate genuine driver cancer-causing mutations from stochastic passenger events in the cancer genome without any functional consequence.<br>- Identify the differences in the cellular inflammatory transcriptone in AYAs and Elderly.<br>- Identify genotype/gene-expression/phenotype correlation.